Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.

Each quarter, Locust Walk deal team members compile compile key statistics and performance indicators on the latest Medtech transactions. Our Q2 2018 Trends in Medtech Transactions report applies the latest data to analyze current activities in the life science deal landscape. ​

In this quarter’s report you can find an overview and analysis of the following medtech activities: ​

• Key performance indicators for the medtech market​​
• Private financing activity and performance​​
• Deal activity for M&A

    

SUMMARY OF FINDINGS:

M&A deals in Q2 2018 targeted innovative technologies across a spectrum of therapeutic areas 

• Boston Scientific acquisition of NxThera ($406.0M)
• Boston Scientific acquisition of nVision Medical ($275.0M)
• QIAGEN acquisition of STAT-Dx ($191.0M)
• Illumina acquisition of Edico Genome ($100.0M)
• Boston Scientific acquisition of Securus Medical Group ($50.0M)

Venture funding in the sector has continued at a steady pace 

• Funding to further development of products to streamline surgeries and effectively manage chronic diseases

Limited IPO activity in Q2

• Inspire Medical Systems, a company selling implanted device for treating obstructive sleep apnea raised $108.0M via an IPO on the NYSE
• ElectroCore, a medical device manufacturer backed by the VC arm of Merck raised $78.0M in its NASDAQ IPO to commercialize gammaCore, a new non-drug treatment of pain associated with migraine, in the US

Increasing FDA MedTech approvals

• Greater number of approvals through the de novo 510(k) pathway